



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/778,154

02/05/2001

Seo Hong Yoo

APAP31191-A
072852.0117

5489

7590

03/27/2002

BAKER BOTTS L.L.P.
44TH FLOOR
30 ROCKEFELLER PLAZA
NEW YORK, NY 10112-4498

EXAMINER

KIM, VICKIE Y

ART UNIT

PAPER NUMBER

1614

DATE MAILED: 03/27/2002

7

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Applicati n N .

09/778,154

Applicant(s)

YOO, SEO HONG

Examiner

Vickie Kim

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-147 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-147 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-14, drawn to a method of treating gastritis and peptic ulcer diseases comprising administration of an oral liquid dosage form containing bile acid, starch or non-starch polysaccharide and water
 - II. Claims 15- 22, drawn to a method for treating a liver diseases comprising administration of an oral liquid dosage form containing bile acid, starch or non-starch polysaccharide and water .
 - III. Claims 23-27, drawn to a method for treating gall stones comprising administration of an oral liquid dosage form containing bile acid, starch or non-starch polysaccharide and water
 - IV. Claims 28-36, drawn to a method for treating or preventing colorectal adenoma comprising administration of an oral liquid dosage form containing bile acid, starch or non-starch polysaccharide and water
 - V. Claims 37-47 , drawn to a method for treating hyperlipidemia comprising administration of an oral liquid dosage form containing bile acid, starch or non-starch polysaccharide and water.
 - VI. Claims 48-77, 81 and 138-147, drawn to a clear aqueous composition comprising a bile acid or its analogs, an aqueous soluble non-starch polysaccharide and water.

- VII. Claims 78-80, drawn to a method of preparing an aqueous solution of group VI.
- VIII. Claims 82-87, drawn to a clear aqueous solution comprising a bile acid containing first material, a second material containing an aqueous soluble starch or non-starch polysaccharide, a third material comprising an aqueous soluble bismuth compound and water.
- VIII. Claims 97-128, drawn to a method of increasing or decreasing the enterohepatic bile acid ; increasing the blood concentration of intact bile acid ; or increasing or decreasing absorption and elimination of intact bile acid comprising administration of an oral liquid dosage form containing bile acid, starch or non-starch polysaccharide and water.

2. Inventions (VI or VIII) and (I-V, VIII) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)).

3. Inventions (VI or VIII) and VII are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)).

Art Unit: 1614

4. Inventions I, II, II, IV, V and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).

5. Inventions V and VIII are independent and distinct, each from the other, as they have acquired a separate status in the art and/or require independent searches. It is noted that a reference to one combination of drugs would not be a reference to another combination of drugs under U.S. C. 103. Further, the claims read on a multitude of combinations of drugs which would require many field of searches that would be an undue burden on the examiner. Therefore, restriction for examination purposes is proper.

6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and the search required for each group is not same, wherein a reference which anticipates the invention of Group I would not render the invention of Group II or III obvious, absent ancillary art, restriction for examination purposes as indicated is proper. Even if there were unity of classification, the search of entire groups and/or genus in the non-patent literature(especially, non-patent literature) and database search (a significant part of a thorough examination) would be burdensome, it is undue burden for examiner for the accurate and proper examination, restriction for examination purposes as indicated is proper.

Election of speices

7. Upon the election of the group that contains patentably distinct invention, applicant is further required to elect the speices of the each component. This application contains claims directed to the following patentably distinct species of the claimed invention: Firstly, the claims include various bile acid analogs including bile acid, its salts , its derivatives and a bile acid conjugated with an amine. For instance, Claim 61 is listing various patentably distinct species of bile acid. Secondly the claims include patentably distinct species found in second material(e.g. starch conversion product or non-starch polysaccharide). In the case of that group VIII is elected, applicant is required to elect the species mentioned immediately above(i.e. first and second material) and found in specific utility(i.e claim 97, 104, 111, 120 or 129).

The various sets of combinations comprising different first material and second material are independent and distinct, each from the other, as they have acquired a separate status in the art and/or require independent searches.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims

are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.


Conclusion

All the pending claims are subject to restriction/election requirement.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is (703) 305-1675 (Tuesday-Friday: 8AM-6:30PM).

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Vickie Kim,
Patent examiner
March 25, 2002


William Jarvis
Primary examiner
Art unit 1614